Estimating the disease burden of methicillin-resistant Staphylococcus aureus in Japan: Retrospective database study of Japanese hospitals

Abstract

ObjectivesThe nationwide impact of antimicrobial-resistant infections on healthcare facilities throughout Japan has yet to be examined. This study aimed to estimate the disease burden of methicillin-resistant Staphylococcus aureus (MRSA) infections in Japanese hospitals.DesignRetrospective analysis of inpatients comparing outcomes between subjects with and without MRSA infection.Data sourceA nationwide administrative claims database.Setting1133 acute care hospitals throughout Japan.ParticipantsAll surgical and non-surgical inpatients who were discharged between April 1, 2014 and March 31, 2015.Main outcome measuresDisease burden was assessed using hospitalization costs, length of stay, and in-hospital mortality. Using a unique method of infection identification, we categorized patients into an anti-MRSA drug group and a control group based on anti-MRSA drug utilization. To estimate the burden of MRSA infections, we calculated the differences in outcome measures between these two groups. The estimates were extrapolated to all 1584 acute care hospitals in Japan that have adopted a prospective payment system.ResultsWe categorized 93 838 patients into the anti-MRSA drug group and 2 181 827 patients into the control group. The mean hospitalization costs, length of stay, and in-hospital mortality of the anti-MRSA drug group were US$33 548, 75.7 days, and 22.9%, respectively; these values were 3.43, 2.95, and 3.66 times that of the control group, respectively. When extrapolated to the 1584 hospitals, the total incremental burden of MRSA was estimated to be US$2 billion (3.41% of total hospitalization costs), 4.34 million days (3.02% of total length of stay), and 14.3 thousand deaths (3.62% of total mortality).ConclusionsThis study quantified the approximate disease burden of MRSA infections in Japan. These findings can inform policymakers on the burden of antimicrobial-resistant infections and support the application of infection prevention programs.

Hospitalization costs and length of stay of Japanese children with respiratory syncytial virus

“…Lower health care costs in Japan compared to the United States for other conditions such as leukemia [ 41 ] have also been reported or antimicrobial-resistant infections. [ 42 ] The main reason is due to differences in health care systems between the 2 countries. For instance, the health care market in the United States is largely unregulated in terms of price setting with much higher prices for both health care and therapeutic services.…”

Streptomyces as a Prominent Resource of Future Anti-MRSA Drugs

“…These secondary infections lead to increased healthcare costs, resulting from prolonged hospital stay and additional antibiotics (Nelson et al, 2015 ). In Japan alone, a recent comprehensive comparative cost analysis for MRSA has been estimated to be greater than all other non-MRSA infection (Uematsu et al, 2017 ). As an indication of the scale of the threat posed by these organisms, in the USA, MRSA kills more people than HIV and TB combined (Boucher and Corey, 2008 ).…”

Safety, tolerability, and immunogenicity of a novel 4-antigen Staphylococcus aureus vaccine (SA4Ag) in healthy Japanese adults

“…2 The annual incidence of methicillin-resistant S. aureus (MRSA) infection in Japan was 3.1 per 1,000 inpatients in 2016, 3 and hospitalized surgical and nonsurgical inpatients with MRSA infections had much higher hospitalization costs, length of stay, and inhospital mortality than those without MRSA. 4 S. aureus is the most common cause of surgical-site infections (SSIs) globally. 5 In Japan, S. aureus was the second leading cause of SSIs, accounting for approximately 9% of clinical isolates from SSIs in 2016, 6 with MRSA comprising approximately half (49% to 54%) of S. aureus SSIs.…”

“…4. Proportion of participants with local vaccination-site reactions and systemic events within 14 days of vaccination.…”